JOHNSON & JOHNSON’s PROCRIT (EPOETIN) SALES DOUBLE IN U.S. IN FOURTH QUARTER, FIRM TELLS ANALYSTS; RISPERDAL ANTIPSYCHOTIC NDA AT FDA SINCE APRIL